Osang Healthcare Co.,Ltd (036220) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Osang Healthcare Co.,Ltd stock KRW 7,222, price KRW 4,890, upside +47.7%, quality 54 out of 100. Rating: undervalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 2,048 KRW – 27,578 KRW · fair‑value band 5,055 KRW – 9,388 KRW · the 4,890 KRW price screens below the 7,222 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Osang Healthcare Co. in your weekly email
Every Wednesday you see whether Osang Healthcare Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Osang Healthcare Co.,Ltd researches, develops, and sells various diagnostic biosensors in South Korea and internationally. The company offers diagnostic biosensors for blood glucose, hemoglobin A1c, cholesterol, immuno diagnosis, molecular diagnosis, and others.
Show moreShow less
It also exports its products to approximately 110 countries worldwide. The company was formerly known as Infopia Co., Ltd. and changed its name to Osang Healthcare Co.,Ltd in April 2017. Osang Healthcare Co.,Ltd was founded in 1996 and is headquartered in Anyang-si, South Korea.
Stock analysis
Osang Healthcare Co.,Ltd (036220) currently trades at 4,890 KRW, while our model-based Fair Value estimate is 7,222 KRW, implying the stock looks roughly 32% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 7,222 KRW per share, and 10 of the 16 models we run sit above the 4,890 KRW price.
Bear case: the Asset-Based group reads lowest at 3,389 KRW, and 6 of the 16 models stay below the price. Data coverage for this calculation is low.
Scenario range: 5,055 KRW (bear) to 9,388 KRW (bull), the price of 4,890 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Osang Healthcare Co.,Ltd reported revenue of 129B KRW in FY2025 versus 132B KRW in FY2021, a compound −0.7%/yr. Reported net income was 3.1B KRW in FY2025, compounding +20.8%/yr from FY2021.
Key figures
Market cap 69.0B KRW (≈ $51.0M) Micro · P/S ratio 0.76 · EPS (TTM) −615.87 KRW · Dividend yield 4.1% · Net margin −8.8% · Return on equity −3.1% · Return on assets (EBIT) 10.6% (5-year average) · Operating margin −42.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 19 out of 100 (medium confidence).
What moves the price
The share trades about 64% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 48%, 036220 screens cheaper than that median.
Fair Value models
Bear5,055 KRWFair Value 7,222 KRWBull9,388 KRW
Price 4,890 KRW · Upside +47.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.20/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+59.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.8%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+18.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+14.3%
Dividend (yield on the price)4.1%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−5% → 2%
Compare Osang Healthcare Co.,Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score54 · Above median
Fair Value upside+47.7% · Top 25%
Profitability
Return on assets0.9% · Below median
Net margin (12 months)−8.8% · Bottom 25%
Operating margin (12 months)−42.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−54.5% · Bottom 25%
Dividend yield (12 months)4.1% · Top 25%
Balance sheet
Debt / equity0.11× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Osang Healthcare Co.,Ltd (036220) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 7,222 KRW versus a price of 4,890 KRW, about +48% upside (undervalued).
What is the fair value of 036220?
Our model-based fair value for Osang Healthcare Co.,Ltd is 7,222 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 4,890 KRW.
What is the quality score of 036220?
Osang Healthcare Co.,Ltd has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Osang Healthcare Co.,Ltd (036220)?
Our model-based price target is the fair value of 7,222 KRW (as of Nov 9, 2026) from 16 valuation models. Cautious scenario 5,055 KRW, optimistic scenario 9,388 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Osang Healthcare Co.,Ltd stock forecast for 2026?
Our models put fair value at 7,222 KRW, about +48% upside versus a price of 4,890 KRW (undervalued). Cautious scenario 5,055 KRW, optimistic scenario 9,388 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Osang Healthcare Co.,Ltd (036220)?
Osang Healthcare Co.,Ltd reported trailing-twelve-month revenue of about 96.5B KRW (latest available figure, as of Nov 9, 2026).
Does Osang Healthcare Co.,Ltd pay a dividend?
Osang Healthcare Co.,Ltd currently shows a dividend yield of 4.09% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Osang Healthcare Co.,Ltd (036220) and when is the ex-dividend date?
Osang Healthcare Co.,Ltd pays a dividend of 200.00 KRW per share a year, a dividend yield of 4.1%. The last ex-dividend date was Mar 30, 2026. The payout ratio is 88.3% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Osang Healthcare Co.,Ltd (036220)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Osang Healthcare Co.,Ltd it is 7,222 KRW per share (as of Nov 9, 2026), against a price of 4,890 KRW. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Osang Healthcare Co.,Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 036220 trades below its calculated fair value: price 4,890 KRW, fair value 7,222 KRW, a gap of about +48% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 036220?
No. The price is what the market pays today (4,890 KRW); the fair value is what the company's own numbers justify (7,222 KRW). For Osang Healthcare Co.,Ltd the two are 2,332 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Osang Healthcare Co.,Ltd worth?
The market values Osang Healthcare Co.,Ltd at about 69.0B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 4,890 KRW; our models calculate a fair value of 7,222 KRW per share.
What do the bullish and bearish scenarios say about 036220?
Our models span a range for Osang Healthcare Co.,Ltd: cautious scenario 5,055 KRW, base 7,222 KRW, optimistic 9,388 KRW per share (as of Nov 9, 2026, price 4,890 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Osang Healthcare Co.,Ltd (036220)?
Balance-sheet figures for Osang Healthcare Co.,Ltd (as of Nov 9, 2026): return on equity −3.1%, debt of 0.11 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is 036220 from its 52-week high?
Osang Healthcare Co.,Ltd trades at 4,890 KRW, about 64% below its 52-week high of 13,553 KRW and at the low of 4,890 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 7,222 KRW is for.
Which stocks are comparable to Osang Healthcare Co.,Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Osang Healthcare Co.,Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 4,890 KRW, calculated fair value 7,222 KRW (+48%), Quality Score 54/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 036220 calculated?
We run Osang Healthcare Co.,Ltd through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 7,222 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Osang Healthcare Co.,Ltd currently trades 32% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Osang Healthcare Co.,Ltd (036220)?
The closing price on Nov 6, 2026 was 4,890 KRW. Our model-based fair value is 7,222 KRW, about +48% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Osang Healthcare Co.,Ltd right now?
The price is below even our cautious bear case (5,055 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (54/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (5,055 KRW to 9,388 KRW) leaves room in how you read the outcome.
Key figures of Osang Healthcare Co.,Ltd
How large is the market capitalisation of Osang Healthcare Co.,Ltd (036220)?
The market capitalisation of Osang Healthcare Co.,Ltd is 69.0B KRW (≈ $51.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Osang Healthcare Co.,Ltd (036220)?
The price-to-sales ratio of Osang Healthcare Co.,Ltd is 0.76 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Osang Healthcare Co.,Ltd (036220)?
Earnings per share at Osang Healthcare Co.,Ltd are −615.87 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Osang Healthcare Co.,Ltd (036220)?
The dividend yield of Osang Healthcare Co.,Ltd is 4.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Osang Healthcare Co.,Ltd (036220)?
The net margin of Osang Healthcare Co.,Ltd is −8.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Osang Healthcare Co.,Ltd (036220)?
The return on equity (ROE) of Osang Healthcare Co.,Ltd is −3.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Osang Healthcare Co.,Ltd (036220)?
On an EBIT basis the return on assets of Osang Healthcare Co.,Ltd is 10.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Osang Healthcare Co.,Ltd (036220)?
The operating margin of Osang Healthcare Co.,Ltd is −42.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Osang Healthcare Co.,Ltd (036220)?
Revenue at Osang Healthcare Co.,Ltd is growing −54.5% versus a year earlier (3y avg −12.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Osang Healthcare Co.,Ltd (036220) generate?
The free cash flow of Osang Healthcare Co.,Ltd is −12.8B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Osang Healthcare Co.,Ltd (036220) carry?
The net debt of Osang Healthcare Co.,Ltd is 22.3B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Osang Healthcare Co.,Ltd in the live analysis
One click puts Osang Healthcare Co.,Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026